Jan Müller-Brand Selected Research

yttrium(III)- 1,4,7,10- tetraazacyclotetradecane- N,N',N'',N'''- tetraacetic acid

4/2012	Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.
6/2011	Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.
11/2007	Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jan Müller-Brand Research Topics

Disease

8	Neuroendocrine Tumors (Neuroendocrine Tumor) 03/2017 - 01/2011
7	Neoplasms (Cancer) 03/2017 - 02/2005
3	Diabetes Mellitus 01/2017 - 10/2014
2	Meningioma (Meningiomas) 10/2016 - 02/2015
2	Neoplasm Metastasis (Metastasis) 07/2015 - 01/2010
2	Glioma (Gliomas) 10/2010 - 09/2007
2	medullary Thyroid cancer 01/2010 - 11/2007
2	Thyroid Neoplasms (Thyroid Cancer) 01/2010 - 10/2007
2	Hyperthyroidism 06/2006 - 03/2003
1	Peripheral Arterial Disease 10/2017
1	Gastrinoma 01/2015
1	Ischemia 10/2014
1	Coronary Artery Disease (Coronary Atherosclerosis) 10/2014
1	Cicatrix (Scar) 10/2014
1	Vasculitis (Vasculitides) 02/2012
1	Glioblastoma (Glioblastoma Multiforme) 10/2010
1	Goiter 01/2010
1	Graves Disease (Basedow Disease) 01/2010
1	Hyperplasia 01/2010
1	Disease Progression 01/2010
1	Infections 01/2010
1	Sepsis (Septicemia) 01/2010
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2009
1	Sialadenitis 10/2007
1	Xerostomia 10/2007
1	Hypothyroidism 03/2007
1	Follicular Adenocarcinoma 10/2006
1	Adenoma (Adenomas) 06/2006
1	Shock 06/2006
1	Papillary Carcinoma 06/2006
1	Carcinoma (Carcinomatosis) 06/2006
1	Residual Neoplasm 02/2005
1	Medulloblastoma 02/2005
1	Ventricular Remodeling 08/2004

Drug/Important Bio-Agent (IBA)

7	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 02/2015 - 02/2005
4	edotreotide lutetium LU-177IBA 07/2015 - 01/2011
4	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2013 - 11/2007
3	Edotreotide (SMT 487)IBA 03/2017 - 01/2011
3	Radioisotopes (Radionuclides)IBA 01/2017 - 01/2011
3	Somatostatin Receptors (Somatostatin Receptor)IBA 10/2016 - 01/2013
3	AcidsIBA 04/2012 - 11/2007
3	yttrium(III)- 1,4,7,10- tetraazacyclotetradecane- N,N',N'',N'''- tetraacetic acidIBA 04/2012 - 11/2007
2	Peptide Receptors (Peptide Receptor)IBA 01/2017 - 01/2011
2	DOTA-Tyr(3)- 90Y-octreotideIBA 01/2017 - 02/2015
2	Octreotide (Sandostatin)FDA LinkGeneric 04/2012 - 06/2011
2	Substance PIBA 10/2010 - 09/2007
1	Natriuretic PeptidesIBA 10/2017
1	Brain Natriuretic Peptide (Natrecor)FDA Link 10/2017
1	somatostatin receptor 2IBA 03/2017
1	DOTA(0)-Tyr(3)- 177Lu-octreotideIBA 02/2015
1	omega-Chloroacetophenone (Mace)IBA 10/2014
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 02/2012
1	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 01/2010
1	ProcalcitoninIBA 01/2010
1	AntibodiesIBA 09/2009
1	LigandsIBA 09/2007
1	Antithyroid Agents (Antithyroid Drugs)IBA 03/2007
1	Iodine-131IBA 10/2006
1	CarbimazoleIBA 06/2006
1	isopentaneIBA 06/2006
1	RNA (Ribonucleic Acid)IBA 06/2006
1	Ifosfamide FDA LinkGeneric 02/2005
1	Etoposide (VP 16)FDA LinkGeneric 02/2005
1	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 03/2003

Therapy/Procedure

17	Therapeutics 01/2017 - 06/2006
3	Radiotherapy 01/2013 - 02/2005
2	Aftercare (After-Treatment) 01/2017 - 02/2015
2	Neoadjuvant Therapy 10/2010 - 02/2005
1	Thyroidectomy 01/2010
1	Tooth Extraction (Tooth Extractions) 10/2007
1	Injections 09/2007
1	Adjuvant Chemotherapy 02/2005
1	Drug Therapy (Chemotherapy) 02/2005
1	Brachytherapy 02/2005
1	Stem Cell Transplantation 02/2005
1	Craniospinal Irradiation 02/2005
1	Percutaneous Coronary Intervention 08/2004